Targeting PI3K/Akt/mTOR Signaling in Cancer
Top Cited Papers
Open Access
- 14 April 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 4, 64
Abstract
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.Keywords
This publication has 72 references indexed in Scilit:
- Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitorsBiochemical Journal, 2013
- Targeting PI3K in Cancer: Any Good News?Frontiers in Oncology, 2013
- Regulation and function of mTOR signalling in T cell fate decisionsNature Reviews Immunology, 2012
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysisBritish Journal of Cancer, 2012
- MYC on the Path to CancerCell, 2012
- Akt-dependent and -independent mechanisms of mTOR regulation in cancerCellular Signalling, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005